Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study

Yiding Feng
Zhejiang Cancer Hospital  https://orcid.org/0000-0003-2140-9289
Youhua Jiang
Zhejiang Cancer Hospital
Qiang Zhao
Zhejiang Cancer Hospital
Jinshi Liu
Zhejiang Cancer Hospital
Hangyu Zhang
Zhejiang University School of Medicine First Affiliated Hospital
Qixun Chen (mailto:chenqixun64@sina.com)
https://orcid.org/0000-0003-3434-3004

Research article

Keywords: Esophagogastric junction adenocarcinoma, Lymph nodes, Siewert classification, Surgery

Posted Date: July 16th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-41629/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on November 30th, 2020. See the published version at https://doi.org/10.1186/s12893-020-00926-1.
Abstract

BACKGROUND

The incidence rate of adenocarcinoma of esophagogastric junction (AEG) was significantly increased over the past two decades. Surgery remains the only way to cure. Indeed, there are currently few studies on Chinese AEG patients. The purpose of this study was to retrospectively analyze the survival and prognostic factors of AEG patients in our center.

METHODS

Between January 2008 and September 2014, 249 AEG patients who underwent radical resection were enrolled in this retrospective study, including 196 males and 53 females, with a median age of 64 (range 31–82). Prognostic factors were assessed with Log-rank test, Cox univariate and multivariate analysis.

RESULTS

The 5-year survival rate of all patients was 49%. The median survival time of all enrolled patients was 70.1 months. Pathology type, intraoperative blood transfusion, tumor size, adjuvant chemotherapy, hospital stay days, serum CA199, CA125, CA242 and CEA, pTNM stage, lymphovascular or perineuronal invasion, and the ratio of positive to negative lymph nodes (PNLNR) were significant associated with overall survival when analyzed with univariate analysis.

CONCLUSIONS

Our study found that intraoperative blood transfusion, tumor size, adjuvant chemotherapy, serum CEA and PNLNR, postoperative hospital stays were independent risk factors.

Background

Adenocarcinoma of esophagogastric junction (AEG) was reported to account for about 5–8%[1, 2] of all esophageal cancers in china, and 35.7% of gastric cancers and lower esophageal cancers worldwide[3]. Many population-based studies have showed that the incidence rate of AEG was significantly increased over the past two decades, both in the West countries and in East Asian[4–6]. The reported seven-fold increase in morbidity of AEG [7], which is a more substantial increase than other malignancies, led to a steady increase in mortality from 2–15/100,000 patients[8].

Surgical resection is the main curable treatment for AEG. Unlike gastric cancer, which treated by standard surgical resection plus D2 lymph nodes resection, surgery of AEG is still controversial in many ways, especially for Siewert type II AEG. AEG surgical treatment includes primary tumor removal, lymph node
dissection and reconstruction of the digestive tract. Regional lymph node metastasis is the most common metastasis method of AEG. Studies have found that the lymph node metastasis rate of AEG is 76.3%, much higher than that of distal gastric adenocarcinoma (67.4%)[9]. At the meantime, the distribution of lymph node metastasis in different Siewet subtypes was different, resulting in several different surgical approaches[10, 11] and there are still remain controversies on N staging of AJCC TNM staging system[12]. Other controversial issues include laparoscopic surgery or open surgery, and whether R0 resectable AEG should undergo neoadjuvant chemoradiotherapy.

Based on the above problems, although Siewet classified AEG in 2000, there are still lots of problems exists it clinical practice. As to china, squamous cell carcinoma remains to be the predominant pathological type of esophageal cancer. Therefore, esophageal adenocarcinoma was rarely investigated among Chinese patients. Our study aimed to explore the long outcome of resected AEG Chinese patients and analysis related prognostic factors.

Methods

Patients

From January 2008 to September 2014, there were 420 cases in which curative R0 resection was performed for esophagogastric junction cancers. Data of 420 patients were collected, the inclusion criteria are, (I) patients with pathologically and immunohistochemically diagnosed AEG; (II) patients underwent radical resection and without distant metastasis; (III) patients with Siewert type II AEG. The exclusion criteria are: (I) patients without complete data for analysis; (II) patients with neuroendocrine or other non-adenocarcinoma pathologic types; (III) patients with Siewert type I or III AEG. Among all collected patients, 249 cases had complete clinical data and confirmed postoperative pathology as adenocarcinoma, and meet all inclusion and exclusion criteria.

Data of demographic, comorbidity, pathologic details, surgical approach, blood infusion, hospital stay days, adjuvant therapy and survival time were collected and subsequently analyzed. Among the characteristics, hospital stay days was classified according to whether the patient was hospitalized for more than 10 days or not; the tumor size was classified according whether tumor size was more than 4 cm or not; the tumor pathology was subdivided whether there was lymphovascular invasion or perineuranol invasion. Because the number of lymph nodes dissected varies greatly from different patients, we specifically defined the ratio of positive to negative lymph nodes in all dissected lymph nodes to further differentiate the prognostic differential population, defined as PNLNR (positive lymph nodes/ negative lymph nodes rate).

All postoperative patients in our center are followed up regularly. In general, the frequency of follow-up is every 3 months for the first 2 years, then every 6 months for the following 3 years, and annually thereafter. Telephone follow-up was conducted at irregular intervals. The retrospective study was in
accordance with the ethical standards of the Ethic Committee of Zhejiang Cancer Hospital and received Institutional Review Board approval. No informed consent is needed for this study.

**Surgical approaches selection**

A reasonable surgical route should include tumor resection, lymph node dissection, surgical margin and safety. The alternative AEG surgical approaches include left thoracotomy, Ivor-Leiws, McKeown, transhiatal or abdominal-transhiatal approach. The selection of surgical approaches referred to the NCCN guidelines for Esophageal and Esophagogastric Junction Cancers, NCCN guidelines for Gastric Cancer and Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction. Preoperative staging was referred to the eighth edition of TNM staging system, and preoperative classification was referred to the Siewert type.

In general, abdominal-transhiatal approach preferred for those with esophageal involvement distance < 3 cm, and thoracotomy approach for those with esophageal involvement distance ≥ 3 cm.

**Statistical analyses**

All statistical calculations were performed by the IBM SPSS Statistics (Version 19.0; IBM Corp., New York, USA). Chart making was performed by the GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). The overall survival (OS) was calculated from the surgery date to the date of death due to any cause. Data of patients lost to follow-up were censored at the date of the last observation. The Cox proportional hazards model was used to determine the univariate and multivariate hazards ratios for the study parameters. Pearson product-moment correlation analysis was used to measure the relationship between the two variables. For all tests, P < 0.05 was defined as statistically significant.

**Results**

*Characteristics of patients*

The baseline characteristics of patients are shown in Table 1. There were 196 males and 53 females in the population. The median age of all enrolled patients is 64y, range 31-82y. The details of pathology outcome showed that most patients (72.3%) had pure adenocarcinoma, and the remaining patients had mixed adenocarcinoma with signet ring or mucinous. There were 165 patients with tumors diameters larger than 4cm, and 84 patients with tumor diameters less than or equal to 4cm. Among then, 127 patients had lymphovascular invasion, and 154 patients had perineuronal invasion. Pathological differentiation showed that only 2 patients were G1, G2 accounts for 36.9%, and G3 remain the largest part, accounting for 62.2%.

Among the dissected lymph nodes, 70 patients had no positive lymph nodes, and 32 patients with PNLNR greater than 1, and 147 with PNLNR less than 1. According to TNM stage, there were 23 patients defined as stage I, 45 patients stage II, 94 patients stage III and 87 patients stage IV.
In terms of surgery, there were a total of 3 types of surgical approaches, including 73 cases of left thoracotomy surgery, 1 case of Ivor Lewis surgery, and 175 cases of Transhiatal surgery. Total gastrectomy was performed in 115 patients, and proximal gastrectomy was performed in 134 patients. During surgery, a small part of patients (n=18) received intraoperative blood transfusion. After surgery, 53.4% patients stayed in the hospital more than 10 days, and 46.6% patients stayed less than or equal to 10 days. Long hospital stay is mainly due to postoperative complications, postoperative nutritional status and several other reasons. As to adjuvant chemotherapy, there were 100 patients received adjuvant chemotherapy, and the main chemotherapy regimens were SOX (S-1 and oxaliplatin) and XELOX (capitabin and oxaliplatin).

**Survival data and prognostic factors**

We conducted our last follow-up in October 2019 by telephone, outpatient or inpatient department visit. The median follow-up time was about 75 months. At the last follow-up, 111 patients are still alive. 1-year, 3-year and 5-year survival rate of all enrolled patients were 72%, 59%, and 49%, respectively. The median survival time (mOS) of these patients was 70.1 months (95% CI 53.6-86.6m). Female patients had significant longer survival time than male patients (NA vs. 62.4m). Patients with pure adenocarcinoma had significant longer survival time than mixed pathology patients (85.4 vs. 42.5m). Patients with perineuronal invasion (NA vs. 48.1) or lymphovascular invasion (NA vs. 40.9) had shorter survival time. received blood transfusion (12.4 vs. 81.8) had shorter survival time (Figure 1). Patients received adjuvant chemotherapy (61.7 vs. 93.4) had longer survival time. The median survival time of no lymph node metastasis patients had not reached, while the median survival time of N2 and N3 patients was 64.5m and 24.0m, respectively. As to PNLNR, the mOS of patients with PNLNR≤ 1 was 10.3m, and patients with PNLNR>1 was 1.9m (Figure 2). The mOS of patients whose tumor size more than 4cm had also unreached, while mOS of those tumor size less than or equal to 4cm was 43.8m (Figure 3). pTNM stage was also significant related to survival time. Patients with elevated CA199, CEA, CA242 and AFP had shorter survival time (Table 2). Only 1 of 249 patients died within 30 days after surgery.

Prognostic factors including age, gender, pathology, tumor size, type of surgical approach, serum tumor biomarkers, and blood transfusion. Both univariate and multivariate analyses were applied (Table 2 and Table 3). Among the factors related to survival in univariate analyses, there were 16 factors had significant statistical differences, including gender, pathology, intraoperative blood transfusion, surgical approaches selection, and several serum tumor biomarkers. While factors including type of gastric resection, tumor differentiation, elevated serum AFP and serum ferritin had no significant differences. Then, the multivariate analysis was conducted to identify the predictive indicators for a good prognosis using the parameters which P value less than 0.5 by the univariate analysis. Multivariate analysis showed that intraoperative blood transfusion, tumor size more than 4cm, no adjuvant chemotherapy, higher positive/negative lymph node rate, perineuronal invasion and elevated serum CEA before surgery, stay more than 10 days in hospital after surgery are independent risk factors in resected Siewert type II AEG patients.
Discussion

A number of various surgical approaches are available for Siewert type II AEG patients. With the increasing use of surgery under the laparoscopic or thoracoscopic, the surgical options have become more diversified. Various surgical approaches may lead to varies numbers of dissected lymph nodes, and surgical approaches are strongly associated with prognosis.

Previous studies have suggested that the incidence of espiratory-related complications was noted higher in the thoracotomy group than in the transhiatal group[13–15]. In this study, only 1 patient underwent Ivor Lewis surgery. There was no significant difference in postoperative hospital stay between Left thoracotomy group and Transhiatal group, with a median postoperative hospital stay of 11 days for both groups. But survival was longer in the Transhiatal group than in the thoracotomy group, which was consistent with previous similar studies[13]. Although no convicting theory so far can explain the difference between left thoracotomy and transhiatal, left thoracotomy is considered to be more invasive and have a lower survival benefit. Which may due to the basis of the much higher morbidity after thoracotomy, more and more researches concluded that transhiatal would be better for Siewert type 2 AEG patients.

In previous retrospective studies, perioperative blood transfusions were associated with poor prognosis after surgery for cancer, and were a major independent risk factor for postoperative bacterial infection[16, 17]. Patients receiving intraoperative blood transfusion often have anemia before operation or large intraoperative blood loss during surgery. This study found that the prognosis of patients receiving intraoperative blood transfusion was poor. In this respect, laparoscopic surgery may be more advantageous as a minimally invasive surgery procedure.

When the number of positive lymph node metastases was included in the univariate analysis, it was concluded that patients with different lymph node stages had significant survival differences, but in multiple factors analysis, it does not draw the number of lymph node metastasis were independent risk factors of this conclusion. However, the ratio of positive lymph nodes than negative lymph nodes (PNLNR) acquired significant differences in both univariate and multivariate analysis. This may be because the number of lymph nodes dissected by different surgeries varies a lot, and mere comparison of positive lymph nodes cannot accurately assess the prognosis of patients, while PNLNR is a better predictor of prognosis.

As is known, tumor size is a key factor affecting prognosis, and previous articles used tumor diameter of 4 cm as the dividing line to analyze prognosis[18]. In this study, it was found that tumor size affected prognosis more than T stage and pTNM stage, and patients with tumor size more than 4 cm also with poor prognosis. Moreover, adjuvant study is quite important for resected AEG patients. Oxaliplatin- based systemic chemotherapy has brought significant survival benefits. Elevated serum CEA and perineuronal invasion in pathology were also prognostic factors, which reminds us to conduct thorough preoperative detection, including serum tumor biomarker, and conduct detailed pathological reports.
As our study is a single-center retrospective research, we could not avoid some biases from the incomplete patient data and homogeneous surgical operations. Because of incomplete information on the time of recurrence, we did not conduct statistics on the median time of recurrence and did not analyze the factors affecting recurrence. And our study was unable to record all complications in detail, therefore, we can only indirectly reflect the influence of patient recovery on prognosis from the length of hospital stay. A larger study, preferably a randomized control trial in multiple centers, is needed to regulate the way of Siewert type II AEG patients surgical option.

**Conclusions**

Intraoperative blood transfusion, tumor size, adjuvant chemotherapy, PNLNR, perineuronal invasion and serum CEA, hospital stay after surgery are independent risk factors in resected Siewert type II AEG patients. Transhiatal approach seemed to bring longer survival time than left thoracotomy. And PNLNR is a better prognosis factor than pure N stage.

**Abbreviations**

AEG
adenocarcinoma of esophagogastric junction
PNLNR
ratio of positive to negative lymph nodes
OS
overall survival

**Declarations**

*Ethics approval and consent to participate*

This study was reviewed and approved by the Research and Education Department of the Zhejiang Cancer Hospital. And consent was not required by ethics committee since its a retrospective study.

*Consent for publication*

Not applicable.

*Availability of data and materials*

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

*Competing interests*

The authors declare that they have no competing interests
**Funding**

No funding.

**Authors' contributions**

Feng YD designed the research, collected the data and wrote the paper; Chen QX designed the research and supervised the report; Zhang HY contributed to the statistical analysis; Jiang YH, Zhao Q, Liu JS supervised the report. All authors read and approved the final manuscript.

**Acknowledgements**

The authors thank all the patients who participated in this study.

**References**

1. Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X, Chen W. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 2016;7(2):232–7.
2. Liu S, Dai JY, Yao L, Li X, Reid B, Self S, Ma J, Chang Y, Feng S, Tapsoba Jde D, et al. Esophageal Adenocarcinoma and Its Rare Association with Barrett’s Esophagus in Henan, China. PLoS One. 2014;9(10):e110348.
3. Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, et al. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988–2012: A Single-institution, High-volume Experience in China. Ann Surg. 2016;263(1):88–95.
4. Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13(2):63–73.
5. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998–2003. Int J Cancer. 2008;123(6):1422–8.
6. Dubecz A, Solymosi N, Stadlhuber RJ, Schweigert M, Stein HJ, Peters JH. Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century? - a SEER Database Analysis. J Gastrointest Surg 2013.
7. Pohl H, Sirovich B, Welch HG: Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010, 19(6):1468–1470.
8. Carr JS, Zafar SF, Saba N, Khuri FR, El-Rayes BF. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 2013;44(2):143–51.
9. Liu K, Zhang W, Chen X, Chen X, Yang K, Zhang B, Chen Z, Zhou Z, Hu J. Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China. Medicine. 2015;94(34):e1386.
10. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353–61.

11. Mine S, Kurokawa Y, Takeuchi H, Kishi K, Ito Y, Ohi M, Matsuda T, Hamakawa T, Hasegawa S, Yoshikawa T, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol. 2015;41(10):1348–53.

12. Wang WP, He SL, Yang YS, Chen LQ. Strategies of nodal staging of the TNM system for esophageal cancer. Ann Transl Med. 2018;6(4):77.

13. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M, Japan Clinical Oncology G. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.

14. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.

15. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000. discussion 1000–1001.

16. Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnens AB, Pahlplatz P, Eeftinck Schattenkerk M, Wobbes T, de Vries JE, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344(8922):573–8.

17. Elwood NR, Martin AN, Turrentine FE, Jones RS, Zaydfudim VM. The negative effect of perioperative red blood cell transfusion on morbidity and mortality after major abdominal operations. Am J Surg. 2018;216(3):487–91.

18. Hoshino I, Gunji H, Ishige F, Iwatate Y, Takiguchi N, Ikeda A, Soda H, Tonooka T, Sato N, Kawahara K, et al. Surgical treatment strategy for esophagogastric junction cancers based on the tumor diameter. BMC Surg. 2019;19(1):152.

### Tables

#### Table 1 clinical characteristics of 249 patients
| Characteristics                                      | Case No. (%) |
|-----------------------------------------------------|--------------|
| Gender                                              |              |
| Male                                                | 196 (78.7)   |
| Female                                              | 53 (21.3)    |
| Age                                                 |              |
| Range                                               | 31-82        |
| Median                                              | 64           |
| Type of pathology                                   |              |
| Adenocarcinoma                                      | 180 (72.3)   |
| Adenocarcinoma with partial signet ring or mucinous | 69 (27.7)    |
| Intraoperative blood transfusion                     |              |
| Yes                                                 | 231 (92.8)   |
| No                                                  | 18 (7.2)     |
| Tumor size                                           |              |
| >4 cm                                                | 165 (66.3)   |
| ≤4 cm                                                | 84 (33.7)    |
| pTNM stage                                           |              |
| I                                                    | 23 (9.2)     |
| II                                                   | 45 (18.1)    |
| III                                                  | 94 (37.8)    |
| IV                                                   | 87 (34.9)    |
| Differentiation                                      |              |
| G1                                                   | 2 (0.8)      |
| G2                                                   | 92 (36.9)    |
| G3                                                   | 155 (62.2)   |
| Lymphovascular invasion                             |              |
| Yes                                                  | 127 (51)     |
| No                                                   | 122 (49)     |
| Perineuronal invasion                                |              |
| Yes                                                  | 154 (61.8)   |
| No                                                   | 95 (38.2)    |
| Adjuvant chemotherapy                                |              |
| Yes                                                  | 100 (40.2)   |
| No                                                   | 149 (59.8)   |
| Number of metastatic lymph nodes                    |              |
| Median (range)                                       | 3 (0-38)     |
| PNLNR                                                | 32 (12.9)    |
| >1                                                   | 70 (28.1)    |
| =0                                                   | 147 (59)     |
| ≤ 1                                                  |              |
| Postoperative hospital stays                         |              |
| >10 d                                                | 116 (46.6)   |
| ≤ 10 d                                               |              |
| Type of gastric resection                            |              |
| Total gastrectomy                                    | 115 (46.2)   |
| Proximal gastrectomy                                 | 134 (53.8)   |
| Surgical approach                                    |              |
| Left thoracotomy                                     | 73 (29.3)    |
| Ivor Lewis                                           | 1            |
| Transhiatal                                          | 175 (70.3)   |

PNLNR; positive lymph nodes/ negative lymph nodes rate

Table 2 univariate analysis of survival after surgery
|                            | MST (month) | Univariate analysis | P-value |
|---------------------------|-------------|---------------------|---------|
|                           |             | HR 95% CI           |         |
| (male vs. female)         | 62.4 vs. NA | 1.608 1.019-2.539   | 0.039   |
| (adenovs. versus mix)     | 85.4 vs. 42.5 | 0.632 0.442-1.019 | 0.011   |
| (ansfusion vs. yes)       | 12.4 vs. 81.8 | 0.262 0.903-3.110 | <0.001  |
| (approaches vs. left thoracotomy) | 42.5 vs. 87.6 | 1.569 0.156-1.040 | <0.001  |
| (size ≤4cm vs. >4cm)      | NA vs. 43.8 | 0.410 1.110-0.903  | <0.001  |
| (t chemotherapy vs. no)   | 61.7 vs. 93.4 | 1.477 2.218-1.040 | 0.027   |
| (operative hospital stays ≤10d vs. >10d) | 59.9 vs. 99.7 | 0.806 1.041-0.903 | 0.012   |
| (gastric resection (total vs. proximal)) | 73.5 vs. 64.5 | 0.960 0.274-0.924 | 0.630   |
| (vessel invasion (no vs. yes)) | NA vs. 48.1 | 0.454 0.956-0.924 | <0.001  |
| (vascular invasion (no vs. yes)) | NA vs. 40.9 | 0.448 0.811-0.924 | <0.001  |
| (age)                     | 80 vs. 73 vs. | 1.135 1.041-0.903 | 0.851   |
| (CA199 U/ml (<37 vs. ≥37)) | 24.5 0.784 | 1 0.533 | 0.008   |
| (CEA ng/ml (<5 vs. ≥5))   | 93.4 vs. 31.7 | 0.740 0.310-1.040 | <0.001  |
| (CA242 U/ml (<20 vs. ≥20)) | 80.0 vs. 26.3 | 0.746 0.664-0.878 | 0.010   |
| (CA125 U/ml (<35 vs. ≥35)) | 73.0 vs. 12.0 | 0.605 0.317-0.924 | 0.004   |
| (AFP ng/ml (<10 vs. ≥10)) | 71.4 vs. 70.1 | 1.067 0.634-0.924 | 0.706   |
| (CA724 U/ml (<6.9 vs. ≥6.9)) | 80.3 vs. 51.1 | 0.862 0.117-0.634 | 0.017   |
| (erritin ng/ml (<274.66 vs. ≥274.66)) | 70.1 vs. 80.0 | 0.952 0.745-0.924 | 0.706   |

Table 3 multiple cox regression analysis of survival after surgery
| Variables                                                                 | Multivariate analysis | P-value |
|--------------------------------------------------------------------------|-----------------------|---------|
|                                                                          | HR        | 95%CI   |         |
| Gender (male vs. female)                                                 | 1.250     | 0.981-1.593 | 0.071   |
| Pathology (adeno vs. mix)                                               | 1.066     | 0.864-1.314 | 0.550   |
| Blood transfusion (no vs. yes)                                          | 0.630     | 0.471-0.843 | 0.002   |
| Surgical approaches (left thoracotomy vs. transhiatal)                  | 1.365     | 0.935-1.995 | 0.107   |
| Tumor size (≤4cm vs. >4cm)                                              |           |         |         |
| Postoperative hospital stays (≤10d vs. >10d)                            | 0.728     | 0.582-0.912 | 0.006   |
| PNLNR (>1)                                                              | 0.833     | 0.694-0.999 | 0.048   |
| PNLNR (=0)                                                              | 1         | 1       | <0.001  |
| PNLNR (≤ 1)                                                             | 0.561     | 0.268-1.175 | 0.126   |
| Perineuronal invasion (no vs. yes)                                      | 0.773     | 0.507-1.180 | 0.233   |
| Lymphovascular invasion (no vs. yes)                                    | 0.727     | 0.574-0.922 | 0.008   |
| pTNM stage IV                                                           | 0.899     | 0.721-1.121 | 0.346   |
| stage III                                                               | 1         | 1       | 0.171   |
| stage II                                                                | 1.166     | 0.541-2.512 | 0.694   |
| stage I                                                                 | 0.868     | 0.442-1.707 | 0.682   |
| Serum CA199 (U/ml) (<37 vs. ≥37)                                       | 0.764     | 0.426-1.369 | 0.366   |
| Serum CEA (ng/ml) (<5 vs. ≥5)                                          | 0.986     | 0.784-1.239 | 0.902   |
| Serum CA242 (U/ml) (<20 vs. ≥20)                                       | 0.768     | 0.623-0.947 | 0.014   |
| Serum CA125 (U/ml) (<35 vs. ≥35)                                       | 0.934     | 0.707-1.233 | 0.629   |
| Adjuvant chemotherapy (no vs. yes)                                      | 0.739     | 0.490-1.114 | 0.148   |
|                                                                          | 1.478     | 1.214-1.800 | <0.001  |

**Figures**
Figure 1

The mOS of patients without intraoperative blood transfusion is 81.8m (a) and patients with intraoperative blood transfusion is 12.4m (b), p<0.001.
Figure 2

The mOS of patients with PNLNR>1 was 1.9m (c), patients with PNLNR≤ 1 (b) was 10.3m, and patients with PNLNR=0 had not reached (a), p<0.001.
The median overall survival (mOS) of patients with tumor diameter more than 4cm had not reached (a), and mOS of tumor diameter less or equal to 4cm was 43.8m (b), p<0.001.